At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,296 enrolled
Drug / intervention
80 mg Ixekizumab Dosing Regimens 1, 2, and 3 +1 moredrug
Likely dose
80 mg Ixekizumab Dosing Regimens 1, 2, and 3from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 and Placebo for Psoriasis. Completed, enrolled 1,296 participants across 104 sites in 11 countries.
Detailed Summary
This study will assess the safety and efficacy of LY2439821 compared to placebo in participants with moderate to severe, chronic plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesAustralia, Canada, Denmark, Germany, Hungary, Italy, Japan, Poland, Romania, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2011
First PostedNov 2011
Primary CompletionJun 2014
Study CompletionSep 2018
TodayJul 2026
First PostedNov 18, 2011
Enrollment StartNov 16, 2011
Primary CompletionJun 24, 2014
Study CompletionSep 20, 2018
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 14.6 years ago
Interventions
80 mg Ixekizumab Dosing Regimens 1, 2, and 3drug
Administered SC
Placebodrug
Administered SC